Tritium and deuterium labelling of a kainate receptor antagonist and evaluation as a radioligand
Paulina Chałupnik,Aleš Marek,Marie Emilie Leiticia Hovah,Darryl S. Pickering,Piero Temperini,Stephanie Donbosco,Ewa Szymańska,Tommy N. Johansen
DOI: https://doi.org/10.1002/jlcr.4087
2024-02-10
Journal of Labelled Compounds and Radiopharmaceuticals
Abstract:Using a dehalogenation strategy, we have effectively labelled a potent GluK3 and GluK1‐preferring competitive kainate receptor antagonist. Radioligand binding studies conducted with [3H]‐1 demonstrated applicability for selectively studying native GluK3 receptors in the presence of selective GluK1 and AMPA receptor‐blocking ligands. Kainate receptors play a crucial role in mediating synaptic transmission within the central nervous system. However, the lack of selective pharmacological tool compounds for the GluK3 subunit represents a significant challenge in studying these receptors. Recently presented compound 1 stands out as a potent antagonist of GluK3 receptors, exhibiting nanomolar affinity at GluK3 receptors and strongly inhibiting glutamate‐induced currents at homomeric GluK1 and GluK3 receptors in HEK293 cells with Kb values of 65 and 39 nM, respectively. This study presents the synthesis of two potent GluK3‐preferring iodine derivatives of compound 1, serving as precursors for radiolabelling. Furthermore, we demonstrate the optimisation of dehalogenation conditions using hydrogen and deuterium, resulting in [2H]‐1, and demonstrate the efficient synthesis of the radioligand [3H]‐1 with a specific activity of 1.48 TBq/mmol (40.1 Ci/mmol). Radioligand binding studies conducted with [3H]‐1 as a radiotracer at GluK1, GluK2, and GluK3 receptors expressed in Sf9 and rat P2 membranes demonstrated its potential applicability for selectively studying native GluK3 receptors in the presence of GluK1 and 2‐amino‐3‐hydroxy‐5‐methyl‐4‐isoxazolepropionic acid (AMPA) receptor‐blocking ligands.
chemistry, medicinal,biochemical research methods, analytical